Artículos de revistas
BDNF as a biomarker of cognition in schizophrenia/psychosis: An updated review
Fecha
2021Registro en:
Frontiers in Psychiatry June 2021 | Volume 12 | Article 662407
10.3389/fpsyt.2021.662407
Autor
Nieto Rojas, Rodrigo Antonio
Carrasco, Andrea
Corral Zavala, Sebastián Andrés
Castillo, Rolando
Gaspar Ramos, Pablo Arturo
Bustamante Calderón, María Leonor
Silva, Hernán
Institución
Resumen
Brain Derived Neurotrophic Factor (BDNF) has been linked to cognitive symptoms of
schizophrenia, which has been documented in previous reviews by several authors.
However, a trend has recently emerged in this field moving from studying schizophrenia
as a disease to studying psychosis as a group. This review article focuses on recent
BDNF studies in relation to cognition in human subjects during different stages of the
psychotic process, including subjects at high risk of developing psychosis, patients at
their first episode of psychosis, and patients with chronic schizophrenia. We aim to
provide an update of BDNF as a biomarker of cognitive function on human subjects with
schizophrenia or earlier stages of psychosis, covering new trends, controversies, current
research gaps, and suggest potential future developments in the field. We found that
most of current research regarding BDNF and cognitive symptoms in psychosis is done
around schizophrenia as a disease. Therefore, it is necessary to expand the study of the
relationship between BDNF and cognitive symptoms to psychotic illnesses of different
stages and origins.